ArticleFuture science OA2025
Web-based predictive tool for vaginal and vulvar melanomas: a machine learning study.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne in every 41 women develops malignant melanoma in their lifetime, with noncutaneous melanomas arising in areas such as the genitourinary (GU) system being particularly rare and aggressive. We used machine learning (ML) to build prognostic models for vaginal (VaM) and vulvar (VuM) melanomas and developed the first predictive web-based tool for survival in these cancers.
methodsWe leveraged the SEER database (2000-2020) to assemble our cohort and extract relevant clinical and demographic variables. Prognostic factors were screened using univariate and multivariate Cox proportional hazards regression analyses. Subsequently, we developed five machine-learning classifiers to predict 5-year survival. The discrimination of each model was assessed using the area under the receiver operating characteristic curve (AUC-ROC), and calibration was examined to ensure reliability. Kaplan-Meier analyses were performed to visualize survival distributions across key subgroups.
resultsThis study included 1575 patients, of whom 372 and 1203 had VaM and VuM, respectively. The median patient age was 67 years, and the median tumor size was 2.4 cm. The 5-year survival rate of patients with VuM (45.4%) was significantly higher than that of patients with VaM (15.2%) (P < 0.001).
conclusionsThis study highlights the aggressive nature of rare GU melanomas and the importance of surgical intervention and caution in the use of chemotherapy and radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.